• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    26 Stocks Moving in Tuesday's Pre-Market Session

    12/21/21 6:55:26 AM ET
    $ADGI
    $ALDX
    $AQST
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email

    Gainers

    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains effectiveness against the omicron variant, other covid-19 variants, SARS, MERS, and the common cold human coronaviruses.
    • Reliance Global Group, Inc. (NASDAQ:RELI) rose 77.4% to $5.41 in pre-market trading after gaining around 6% on Monday.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) rose 39.5% to $2.58 in pre-market trading after declining around 14% on Monday. Quoin Pharma recently announced an exclusive distribution agreement with Orpharm LLC for QRX003. Under the agreement terms, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS.
    • Biofrontera Inc. (NASDAQ:BFRI) rose 22.2% to $9.31 in pre-market trading after gaining over 7% on Monday. Biofrontera recently announced the first subject has been enrolled in the Phase 2b study to evaluate the safety and efficacy of Ameluz in combination with the red-light lamp BF-RhodoLED for acne.
    • uCloudlink Group Inc. (NASDAQ:UCL) rose 16.1% to $3.10 in pre-market trading following a 9% gain on Monday.
    • Society Pass Incorporated (NASDAQ:SOPA) rose 15.7% to $13.03 in pre-market trading. Society Pass shares jumped 240% on Monday after the company was added to the Russell 2000.
    • CooTek (Cayman) Inc. (NYSE:CTK) rose 9.3% to $0.5480 in pre-market trading. CooTek recently announced its Fengdu Novel reached a collaboration with Tencent Video's Mars Project.
    • China Xiangtai Food Co., Ltd. (NASDAQ:PLIN) rose 7.4% to $1.74 in pre-market trading. China Xiangtai Food recently reported the launch of U.S. operation with new U.S. headquarter office in New York City.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) shares rose 7.1% to $39.37 in pre-market trading after dropping 15% on Monday.
    • Tuya Inc. (NYSE:TUYA) rose 7.1% to $5.75 in pre-market trading after tumbling around 18% on Monday.
    • Datasea Inc. (NASDAQ:DTSS) shares rose 7% to $1.52 in pre-market trading.
    • Micron Technology, Inc. (NASDAQ:MU) rose 6.8% to $87.65 in pre-market trading after the company reported upbeat results for its first quarter and issued strong revenue guidance for the current quarter.
    • Universe Pharmaceuticals INC (NASDAQ:UPC) rose 6.6% to $1.78 in pre-market trading. Universe Pharmaceuticals recently named Mr. Baochang Liu as Chief Operating Officer.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) rose 6.6% to $0.3950 in pre-market trading. The company’s CEO Saundra L Pelletier bought 135,000 shares at an average price of $0.38 per share.
    • PLBY Group, Inc. (NASDAQ:PLBY) rose 5.1% to $30.01 in pre-market trading. PLBY Group owned lifestyle brand Playboy has launched CENTERFOLD, a creator-led platform.
    • NIKE, Inc. (NYSE:NKE) rose 3.5% to $162.49 in pre-market trading as the company reported stronger-than-expected results for its second quarter on Monday.


    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Check out these big penny stock gainers and losers

    Losers

    • Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) fell 35.9% to $4.57 in pre-market trading after the company reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial failed to meet the primary endpoint of ocular redness, but it did achieve statistical significance for the dry eye disease sign of the Schirmer test, a secondary endpoint..
    • Aquestive Therapeutics, Inc. (NASDAQ:AQST) fell 33.1% to $4.16 in pre-market trading after the company said it received notification from the FDA that it will not be ready to take action by december 23, 2021 for the company's NDA for Libervant Buccal Film.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) fell 22.5% to $5.00 in pre-market trading after the company announced preliminary results for the ongoing Phase 2 expansion study of CX-2029.
    • DBV Technologies S.A. (NASDAQ:DBVT) fell 16.7% to $2.25 in pre-market trading after the company issued an update on investigational Viaskin Peanut patch. The company said it has decided not to pursue sequential approach to development plans for Viaskin Peanut.
    • SeaChange International, Inc. (NASDAQ:SEAC) fell 11.4% to $1.86 in pre-market trading after rising more than 36% on Monday. SeaChange International recently reported better-than-expected Q3 results.
    • Bridgeline Digital, Inc. (NASDAQ:BLIN) shares fell 10% to $2.43 in pre-market trading after the company swung to a loss in the fourth quarter.
    • Can-Fite BioPharma Ltd. (NYSE:CANF) shares fell 8.8% to $1.96 in pre-market trading after the company reported exercise of warrants for cash proceeds of $10 million.
    • Genfit SA (NASDAQ:GNFT) shares fell 7.1% to $5.25 in pre-market trading after gaining 11% on Monday.
    • Adagio Therapeutics, Inc. (NASDAQ:ADGI) shares fell 6% to $9.40 in pre-market trading after declining around 13% on Monday.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) shares fell 5.1% to $0.5410 in pre-market trading after jumping 12% on Monday.
    Get the next $ADGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGI
    $ALDX
    $AQST
    $ARDS

    CompanyDatePrice TargetRatingAnalyst
    Micron Technology Inc.
    $MU
    1/23/2026$350.00 → $500.00Buy
    HSBC Securities
    Micron Technology Inc.
    $MU
    1/22/2026Outperform
    William Blair
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Micron Technology Inc.
    $MU
    1/20/2026$300.00 → $450.00Buy
    TD Cowen
    Micron Technology Inc.
    $MU
    1/16/2026$275.00 → $450.00Overweight
    Barclays
    Micron Technology Inc.
    $MU
    1/15/2026$425.00Outperform
    RBC Capital Mkts
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    More analyst ratings

    $ADGI
    $ALDX
    $AQST
    $ARDS
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    2/11/26 4:06:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.

    SCHEDULE 13G/A - Biofrontera Inc. (0001858685) (Subject)

    2/11/26 11:31:16 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by uCloudlink Group Inc.

    SCHEDULE 13G/A - uCloudlink Group Inc. (0001775898) (Subject)

    2/11/26 6:35:55 AM ET
    $UCL
    Telecommunications Equipment
    Consumer Discretionary

    $ADGI
    $ALDX
    $AQST
    $ARDS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Society Pass Incorporated Announces Pricing of $3.0 Million Public Offering of Common Stock

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Society Pass Incorporated (NASDAQ:SOPA) (the "Company"), Southeast Asia's (SEA) next generation e-commerce ecosystem, today announced the pricing of its best efforts public offering of an aggregate of 5,381,819 shares of its common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.55 per share (or per common stock equivalent in lieu thereof), for aggregate gross proceeds of approximately $3.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on February 13, 2026, subject to satisfaction of customary closing conditions. Rodm

    2/11/26 9:30:00 PM ET
    $SOPA
    Real Estate

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Society Pass Incorporated (Nasdaq: SOPA) and NusaTrip Incorporated (Nasdaq: NUTR) Strengthened its Presence in the Tourism Market with Collaboration with Qi You Ji Network Technology Co. Limited

    JAKARTA, Indonesia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Society Pass Incorporated (NASDAQ:SOPA) (the "Company" or "SOPA"), Southeast Asia's (SEA) next generation e-commerce ecosystem, and its majority owned subsidiary, NusaTrip Incorporated (NASDAQ:NUTR) ("NusaTrip"), the leading SEA and Asia-Pacific-based (APAC) integrated travel technology platform, today announced the expansion of its hotel distribution network, further strengthening its presence in the tourism market through its collaboration with Hong Kong, China-based Qi You Ji Network Technology Co. Limited ("QiYouJi"). This collaboration enables NusaTrip's downstream customers to access a broader selection of competitively priced h

    2/11/26 11:00:00 AM ET
    $NUTR
    $SOPA
    Transportation Services
    Consumer Discretionary
    Real Estate

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Business Officer Sadana Sumit sold $10,747,266 worth of shares (25,000 units at $429.89), decreasing direct ownership by 9% to 248,021 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    2/4/26 7:03:49 PM ET
    $MU
    Semiconductors
    Technology

    Chairman Emeritus Knight Philip H converted options into 4,500,000 units of Class B Common Stock, increasing direct ownership by 54% to 12,835,687 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/4/26 6:13:42 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Chief Business Officer Lester Rachael was granted 20,000 shares (SEC Form 4)

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    2/4/26 4:28:36 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities reiterated coverage on Micron with a new price target

    HSBC Securities reiterated coverage of Micron with a rating of Buy and set a new price target of $500.00 from $350.00 previously

    1/23/26 10:28:05 AM ET
    $MU
    Semiconductors
    Technology

    William Blair initiated coverage on Micron

    William Blair initiated coverage of Micron with a rating of Outperform

    1/22/26 8:29:53 AM ET
    $MU
    Semiconductors
    Technology

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

    Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit in Canada and EU by the end of 2026Company to host investor call on February 2, 2026, at 8:00am ET WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it received a Complete Response Letter (CRL) from the U

    2/2/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces Business Update and Company Milestones for 2026

    - CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ

    1/8/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cassava Reports Q3 2025 Financials Results and Provides Business Update

    Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende

    11/12/25 8:00:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $ALDX
    $AQST
    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bridgeline Digital Inc.

    SC 13G/A - Bridgeline Digital, Inc. (0001378590) (Subject)

    12/13/24 11:31:58 AM ET
    $BLIN
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Bridgeline Digital Inc.

    SC 13G/A - Bridgeline Digital, Inc. (0001378590) (Subject)

    12/2/24 12:08:24 PM ET
    $BLIN
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Bridgeline Digital Inc.

    SC 13G/A - Bridgeline Digital, Inc. (0001378590) (Subject)

    11/25/24 11:42:34 AM ET
    $BLIN
    Computer Software: Prepackaged Software
    Technology